Call for Abstract

15th International Conference on Pharmaceutics and drug safety, will be organized around the theme “Recent Advancements in Pharmacovigilance and Research in Covid-19 Time”

Drug Safety 2022 is comprised of 19 tracks and 77 sessions designed to offer comprehensive sessions that address current issues in Drug Safety 2022.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.


Statistics is playing an important role in clinical research in regulatory submission. Adverse drug reactions report can also be considered for the regulatory submission. Pharmacovigilance process is achieved by ICH guidelines. 




 


  • Track 1-1Drug Safety Updates
  • Track 1-2Drug Safety Solutions
  • Track 1-3 Drug Safety Training
  • Track 1-4Drug Safety Surveillance
  • Track 1-5Drug Safety Services & Software
  • Track 1-6Drug Safety Reporting & Monitoring


Due to some changing resources it is necessary to full-fill the regulatory requirements. Regulatory Affairs department is continuously developed and growing, and the one which is minutely affected during the Acquisition, Merger and recession. The international  drug safety market and Business opportunity was valued at USD 2,408.0 million in 2013 and is predicted to increase at a CAGR of 12.6% at the time of  forecast period. And on the second position it was Phase III clinical trial market and was valued at over USD 750.0 million in 2013.




 



 


  • Track 2-1 Drug safety software Development Companies
  • Track 2-2Business Opportunities for drug safety Software Developing Companies
  • Track 2-3Opportunities for drug safety Software Services companies
  • Track 2-4 Career Growth in drug safety Consulting
  • Track 2-5 Career Growth in drug safety Consulting


  



Clinical data management (CDM) is a complicated process in the field of clinical research, which posses to generation that are of high-quality, reliable, and statistically sound data from clinical trials. The main aim of CDM is to give the sureity about the final data collected from the research.




 


  • Track 3-1Electronic health records
  • Track 3-2Administrative data
  • Track 3-3Claims data
  • Track 3-4Disease registries


 



Drug regulation is a process by which we can control the use of drug by international agreement and through some regulatory authorities like US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceutical and Medical Devices Agency (PMDA).




 


  • Track 4-1 Role of drug regulation
  • Track 4-2Future of medicine regulation


The Pharmaceutical science is an extortionate scope of logical controls of revelation and advancement of newly developed medications and treatments. Pharmaceutical sciences includes the basic fundamental standards of physical and compound science, designing, organic chemistry, and science to see how to upgrade transference of medications to the body and make an interpretation of this coordinated comprehension into as good as ever treatments against human ailment.




 


  • Track 5-1Drug Discovery and Design
  • Track 5-2Drug Delivery
  • Track 5-3Drug Action
  • Track 5-4Clinical Sciences


Every industry is developed more rapidly. Products and administrations are growing increasingly at commercial level. Evolution plays an important part in inquire about and improvement, showcasing and promoting, and deals and dispersion. Only pharmaceutical division has speculated the investigation and advancement over the past few years and also in other sections in a decade time.




 


  • Track 6-1Body sensors clinical trail


The main purpose of this study is to evaluate the prevalence and explain the characteristics of PDDIs  in medical recommendation of hospitalized surgical patients. In this transverse study, we examine 370 medical prescriptions from the surgery unit of a Mexican public teaching hospital. The classification and identification of potential drug-drug interactions were performed with the Micromedex 2.0 electronic drug information database. Results were examined with illustrative statistics and we estimated OR (odds ratio) to determine associated risk factors.




 


  • Track 7-1 Study of Medscape Drug Interaction Checker


In Pharmacoepidemiology we will examine the uses and effects of drugs on the population.  This is the branch of pharmacology and epidemiology Thus, Pharmacoepidemiology is the bridge between pharmacology and epidemiology. In pharmacology we will read about the effect of drugs while in clinical pharmacology we will read about the effect of drugs on clinical humans. Clinical pharmacology provides a risk benefit assessment by effects of drugs in Patients body.




  • Study about pharmacology


  • Study about epidemiology



 


  • Track 8-1Study about pharmacology
  • Track 8-2Study about epidemiology


Quality assurance is a process by which we can prevent the mistakes and defects in manufactured product. So that, when we are delivering the product customers does not face any problem.



 



The study plays crucial role in clinical research program which can be an unexpected association between disease disorders or symptoms like unexpected event occurring during diagnosis, treatment, pathogenesis or adverse effects of diseases. Notable Variation in anatomical structuretherapeutic approaches or salient features is core objective focused in care report.




 


  • Track 10-1Unique therapeutic approaches
  • Track 10-2 Cancer case reports
  • Track 10-3 Cardiovascular trials case report
  • Track 10-4Case studies on sexually transmitted diseases
  • Track 10-5Case studies on type 1 and type 2 diabetes
  • Track 10-6Individual case safety reports
  • Track 10-7 Case studies on type 1 and type 2 diabetes
  • Track 10-8Individual case safety reports


Clinical trials allow drug testing for safety assessment in different population. Preclinical development referred as preclinical studies or nonclinical Studies, is a research stage carried at initial level of increasing accessibility and iterative testing and drug safety data are collected. Main goals of preclinical studies to determine the safe dose in first phase and evaluate the product safety profile. Product may include drugs, gene safety, and diagnostic tools.





  • Expected and un-expected drug reactions and its reporting



 


  • Track 11-1Clinical trials on drugs used in respiratory disorders
  • Track 11-2 Regulatory authorities and ethics committee
  • Track 11-3Multi centre trials and monitoring
  • Track 11-4Alternative trials design and models
  • Track 11-5Data collection and quality control
  • Track 11-6Bioassay and its types
  • Track 11-7 Designing of trials: pre-clinical studies
  • Track 11-8 Scientific Models for Pre-Clinical and Clinical Trials
  • Track 11-9Pre-Clinical Testing
  • Track 11-10 Mechanism of adverse drug reactions
  • Track 11-11Recent clinical trials on AIDS
  • Track 11-12Expected and un-expected drug reactions and its reporting
  • Track 11-13 Classification of various adverse drug reactions


Clinical trial industry is repeatedly growing with diversified clinical research technologies and new clinical studies are being launched at an ever-growing pace. Clinical trials have always been a crucial part of the medicine development process, they provide clinical data for treating pathological disorders and diseases. The importance of diversity in industrial clinical trials and clinical research is to ensure that industrial clinical trials are doing diligence and being strategic possible in results. This diversity makes better understanding in the field of drug safety.




 


  • Track 12-1 SAS Programing in Clinical Research and Pharmaceutical Industry


Its significance Increase the impact of drug safety on patient welfare. This track gives the brief discussion about drug safety and pharmacy in healthcare system. Drug safety protection gives an outlook on the rules and laws to follow in drug safety and pharmacy practice. The Role of Pharma industries works in the improvement of drug safety system crucial to maintain analyze safety assessment data, its Detection and Evaluation of signals manual and medical devices reporting.




  • Significance of drug safety


  • Drug safety and healthcare system


  • Role of pharma industries in the improvement of drug safety system


  • Detection and evaluation of drug safety signals through manual and medical devices reporting



 


  • Track 13-1Significance of drug safety
  • Track 13-2 Drug safety and healthcare system
  • Track 13-3Role of pharma industries in the improvement of drug safety system
  • Track 13-4 Detection and evaluation of drug safety signals through manual and medical devices reporting


Data quality management and analysis in drug safety depend on information collected from individuals. Quality management involves quality control, quality planning, quality assurance, and quality improvement. First step of data collecting cycle is collection of data in system, data entry. Second step is data storage, maintenance followed by data selection. In last data is analyzed. Finally process is concluded to analyze the data.




  1. ·         Data Quality Control and Assurance


  2. ·         Quality Planning and Improvement 


  3.            Data Safety Monitoring


  • Track 14-1Data Quality Control and Assurance
  • Track 14-2 Quality Planning and Improvement
  • Track 14-3 Data Safety Monitoring


It includes various chronic diseases like: AIDS, Benign and Malignant tumor, Diabetes, Clinical Trials of Monoclonal and Polyclonal antibodies, neurological, physiological and psycological disorder.



 




 


  • Track 15-1Emerging technology in clinical trials
  • Track 15-2Recent clinical trials on AIDS
  • Track 15-3Clinical trials on benign and malignant tumors
  • Track 15-4Clinical trials on cardiovascular diseases
  • Track 15-5Clinical trials on diabetes
  • Track 15-6 Clinical trials of monoclonal and polyclonal antibodies
  • Track 15-7 Clinical trials on drugs used in psychological disorders
  • Track 15-8Applications of biomarkers in clinical trials


In this track we will discuss about rational drug management of cancer, diabetes, cardiovascular disorder and management of psychiatric disorders and autoimmune diseaseBioavailability and bioequivalence study plays an important role. International market for biopharmaceutics in 2013 was $ 305.1 million and expected to reach $ 326.3 million in 2014.



 



Pharmacy practice develops the professional role of pharmacists. Include disease state management, pharmacy professional development pharmaceutical drug, clinical drug intervention, pharmaceutical compounding, health physiology drug incompatibility and community pharmacy.




 


  • Track 17-1 Pharmacy practice and its guidelines
  • Track 17-2Challenges in compounding and dispensing practice
  • Track 17-3 Dosage regimen, drug toxicity and drug safety measures
  • Track 17-4Pharmacoepidemiology of drug shortages
  • Track 17-5 Drug labeling


Good Pharmacovigilance practice and pharmacoepidemiology in risk management to increase the possibility of beneficial effects of drug and adverse effects in population maintain reporting practice to avoiding the major problems in risk management. Also concentrate to examine information by collecting drug effects, caused by medicine. Pharmacovigilance and clinical trial services should have Pharmacovigilance certification.




 


  • Track 18-1Role of Pharmacovigilance and pharmacoepidemiology in risk management
  • Track 18-2Good reporting practices
  • Track 18-3Interpreting safety signals
  • Track 18-4 Randomized clinical trials
  • Track 18-5 Ethical and social aspects of drug use


Adverse drug reaction is a form of toxicity or increase drug effect which mainly occurs during efficient use. In US 3-7% hospitalization are due to ADRs. ADRs occur during 10-20% of hospitalizations, 10-20% of ADRs are severe. ADR’s showed no pharmacokinetic effects resulting in 0% death incidence till date. Suggested rate of 0.5 – 0.9% may be high because patient have some serious disorder. Severity and incidence vary through patients characteristic and through drug factors.




 


  • Track 19-1Acute and chronic adverse drug events
  • Track 19-2 Classification of various adverse drug reactions
  • Track 19-3Mechanism of adverse drug reactions
  • Track 19-4 Assessing and reporting adverse drug reactions
  • Track 19-5 Post marketing reports on adverse effects